GeneralBreaking NewsBreakingLatest News
After Sun Pharma Eye-Drop Lapses, Centre Tightens Sterile Medicine Plant Norms
Sentiment: NeutralHigh Priority
What Happened?
The Centre has proposed stricter contamination limits for sterile drug factories after halting production at Sun Pharma's Assam plant due to contamination issues. The new rules align with WHO standards.
Key points
- The Union Health Ministry proposed tighter contamination limits for Grade A zones in sterile drug factories.
- The amendment requires investigation of any microbial growth found in these critical areas.
- Sun Pharma was ordered to halt production after contamination was reported in its Predmet eye drops.
- The All India Ophthalmological Society warned about contamination consistent with Pseudomonas bacteria.
- Sun Pharma recalled 11 ophthalmic products following the contamination issue.
Key insights
- Stricter contamination limits could lead to improved safety in sterile drug production.
- The regulatory changes may prompt other manufacturers to reassess their contamination controls.
- Increased scrutiny on Sun Pharma could affect its reputation and market position.
Why it matters
The new regulations aim to enhance patient safety by ensuring stricter contamination controls in sterile drug manufacturing.
Entities
Sun Pharma· CompanyAssam· StateWorld Health Organisation· OrganizationPseudomonas· Bacteria
Source
India Today
